Navigation Links
FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
Date:1/7/2011

e Patient-Prescriber Agreement, and the enrollment form. These components can be used by all sponsors of immediate release transmucosal fentanyl products to develop individual REMS programs  such as the program approved for Abstral.  FDA has also directed the sponsors of this class of products to work together on a single shared system to implement the REMS.  

"This approval is also a significant step toward reducing the burden on the health care system of implementing REMS programs," added Dr. Jenkins. "When fully implemented, FDA expects that prescribers, pharmacies, and distributors of all immediate release transmucosal fentanyl products will be able to use standardized materials and a single shared system to implement the REMS."

The safety of Abstral was evaluated in 311 opioid-tolerant cancer patients with breakthrough pain.  Two hundred and seventy of these patients were treated in multiple-dose studies. The duration of therapy for patients in multiple-dose studies ranged from 1-405 days with an average duration of 131 days and with 44 patients treated for at least 12 months.

Common adverse reactions include nausea, constipation, drowsiness and headache. Serious adverse events, including deaths, have been reported in patients with other immediate-release transmucosal fentanyl products. The deaths occurred as a result of improper patient selection and/or improper dosing.  

Consumers and health care professionals are encouraged to report adverse side effects or medication errors from the use of Abstral to the FDA's MedWatch Adverse Event Reporting program at http://www.fda.gov/MedWatch or by calling 800-332-1088.

Abstral is manufactured by ProStraken Inc., based in Bedminister, N.J.


'/>"/>

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov


SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
2. FDA Approves New Dosage Strength for INTELENCE®
3. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
4. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
5. FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment
6. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
7. FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury
8. FDA Approves New Treatment Option for Late-Stage Breast Cancer
9. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
10. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
11. FDA Approves New Indication for Afinitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015   Mayo Clinic and ... develop the next generation of wearable biosensors designed to ... that this technology will be game-changer. These patch biosensors ... James Levine, M.D., Ph.D. , a Mayo Clinic ... inexpensive, and can be integrated into the care people ...
(Date:3/4/2015)... 4, 2015  Results of the recent study, ... MarginProbe for Intra-Operative Positive Margin Detection , were presented ... 32 nd Annual Miami Breast Cancer Conference last ... Moshe Papa , MD, FACS, Professor of Surgery at ... reports an analysis of MarginProbe,s efficiency and accuracy when ...
(Date:3/4/2015)...  Bayer HealthCare today announced that the U.S. ... company,s Biologics License Application (BLA) for BAY 81-8973, ... FDA approval of the investigational compound, proposed trade ... in children and adults. "Bayer ... hemophilia A patients who need them," said ...
Breaking Medicine Technology:Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 2Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 3New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3
... Jan. 3, 2012 Reportlinker.com announces that ... in its catalogue: Transdermal ... http://www.reportlinker.com/p0203552/Transdermal-Drug-Delivery---Technologies-Markets-and-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... -Up-to-date one-stop information on transdermal ...
... 3, 2012  When the FDA removed Fen-Phen from the U.S. ... that powerful diet pills had become a thing of the ... burners sprung up almost immediately, and it wasn,t long before ... bags and medicine cabinets. Demand for these ...
Cached Medicine Technology:Transdermal Drug Delivery - Technologies, Markets, and Companies 2Transdermal Drug Delivery - Technologies, Markets, and Companies 3Transdermal Drug Delivery - Technologies, Markets, and Companies 4Transdermal Drug Delivery - Technologies, Markets, and Companies 5Transdermal Drug Delivery - Technologies, Markets, and Companies 6Transdermal Drug Delivery - Technologies, Markets, and Companies 7Transdermal Drug Delivery - Technologies, Markets, and Companies 8Transdermal Drug Delivery - Technologies, Markets, and Companies 9Transdermal Drug Delivery - Technologies, Markets, and Companies 10Transdermal Drug Delivery - Technologies, Markets, and Companies 11BiphedAdrene™, Complex Phenylethylamine Provisional Plus Aggressive Thermogenic Compound, Leads Super-Powerful "Diet Pill" Comeback 2
(Date:3/5/2015)... Brunswick (PRWEB) March 05, 2015 Elandas ... validate product innovations as the company prepares to announce ... be comprised of individuals in the Life Sciences field. ... with our clients,” said Elandas CEO Ryan Roberts. “We ... a successful organization through our collaborative efforts. As we ...
(Date:3/4/2015)... (PRWEB) March 05, 2015 The ... therapeutics landscape over the past decade. The pharmaceutical ... for drug delivery in the form of liposomes ... manifold drugs with more safety and efficiency. ... could perhaps rely greatly upon the enhanced permeability ...
(Date:3/4/2015)... March 04, 2015 Ultraman Florida is ... mile swim, 261.4 mile bike, and 52.4 mile run. ... time of 24:45:45. , "This race was awesome and ... wonderful team and sponsors for supporting me through every ... 2015 had a total of 40 select participants invited ...
(Date:3/4/2015)... TROY Healthcare Solutions will be introducing TROY Secure ... of security for prescriptions, in Houston, Texas on Wednesday, ... located at 6633 Travis Street from 7 AM to ... Healthcare Solutions will host a continental breakfast. Starting at ... each hour to introduce attendees to TROY Secure Print ...
(Date:3/4/2015)... York, NY (PRWEB) March 04, 2015 ... creative, breakthrough marketing campaign called 'We Love Smokers' from ... cravings for tobacco. , "It’s important to establish ... be true to it. Our idea, 'We Love Smokers' ... leadership point of view. We created a bold tone ...
Breaking Medicine News(10 mins):Health News:Elandas Creates Advisory Board to Help Guide Innovation 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3
... to develop a microchip sensitive enough to quickly determine ... that the disease can be detected earlier for more ... in Nature Nanotechnology heralds an era when ... innovation is an indication that the age of nanomedicine ...
... September 28, 2009 NovoCure, Ltd., a privately held ... a non-invasive portable medical device for the treatment of ... today. Key investors in this round included Pfizer Inc, ... "We are very pleased that Pfizer, Johnson & Johnson ...
... poll by the Harvard School of Public Health and The Boston ... state,s health reform legislation, which was enacted in 2006, support it. ... 13% are not sure. The level of public support for the ... they support the law in 2008 to 59% in the current ...
... CA On October 2nd, 2009, Henry Gabelnick PhD, ... prestigious Alan F. Guttmacher lecture at the 2009 ... Los Angeles, California. Reproductive Health 2009 is a ... Planned Parenthood Federation of America National Medical Committee, and ...
... ... recently named to the advisory board for PerfectServe, a healthcare communications company. , ... Knoxville, Tenn. (PRWEB) September ... PerfectServe , a healthcare communications company. The board provides guidance on innovative ways to ...
... ... Research , ... September 28, 2009 -- Axiom Accelerated Patient Recruitment (Axiom), one of the ... messaging (SMS) services. , , , , ,"Mobile device outreach is the future of ...
Cached Medicine News:Health News:U of T researchers create microchip that can detect type and severity of cancer 2Health News:NovoCure Ltd. announces closing of financing round 2Health News:59 percent support Massachusetts' Landmark 2006 health reform law 2Health News:59 percent support Massachusetts' Landmark 2006 health reform law 3Health News:CONRAD executive director to give Guttmacher lecture at Reproductive Health 2009 2Health News:William Fuchs Named to PerfectServe Advisory Board 2Health News:Axiom Accelerated Patient Recruitment Rolls Out 2
... charts incorporate the slight change in the ... Sloan letters derived from the best corrected ... the ETDRS study. The original charts difficulty ... 234 eyes. In addition to the revised ...
... Cube is used to diagnose Stereo and Binocular ... of polarized glasses. The test can be ... visual attention, form and depth perception. The Stereo ... 450 seconds of arc and is ideal for ...
... "natural" Stereotest consists of three test plates(6mm, 3mm, ... in a range of 600 - 15 seconds. ... can only be detected if stereopsis is present. ... risk of the patient learning the correct answer. ...
Lumicon 48 mm red filter....
Medicine Products: